The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora kinase inhibitor GSK1070916A.
Iain McNeish
No relevant relationships to disclose
Alan Anthoney
No relevant relationships to disclose
Paul Loadman
No relevant relationships to disclose
Dan Berney
No relevant relationships to disclose
Simon Joel
No relevant relationships to disclose
Sarah E. R. Halford
No relevant relationships to disclose
Emily Buxton
No relevant relationships to disclose
Amanda Race
No relevant relationships to disclose
Mohammed Ikram
No relevant relationships to disclose
Andrew Scarsbrook
No relevant relationships to disclose
Angela Patikis
No relevant relationships to disclose
Andrea Rockall
No relevant relationships to disclose
Nicola A Dobbs
No relevant relationships to disclose
Christopher Twelves
No relevant relationships to disclose